These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20631802)

  • 1. Progress and prospects: foamy virus vectors enter a new age.
    Erlwein O; McClure MO
    Gene Ther; 2010 Dec; 17(12):1423-9. PubMed ID: 20631802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs.
    Mergia A; Chari S; Kolson DL; Goodenow MM; Ciccarone T
    Virology; 2001 Feb; 280(2):243-52. PubMed ID: 11162838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of efficient, stable and safe replication-deficient foamy virus vectors.
    Bastone P; Romen F; Liu W; Wirtz R; Koch U; Josephson N; Langbein S; Löchelt M
    Gene Ther; 2007 Apr; 14(7):613-20. PubMed ID: 17203107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-level expression of functional foamy virus receptor on hematopoietic progenitor cells.
    von Laer D; Lindemann D; Roscher S; Herwig U; Friel J; Herchenröder O
    Virology; 2001 Sep; 288(1):139-44. PubMed ID: 11543666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of simian immunodeficiency virus by foamy virus vectors expressing siRNAs.
    Park J; Nadeau P; Zucali JR; Johnson CM; Mergia A
    Virology; 2005 Dec; 343(2):275-82. PubMed ID: 16181654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
    Sinn PL; Sauter SL; McCray PB
    Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prospects for gene therapy in hematology].
    Moreau-Gaudry F; Mazurier F; Salesse S; Fontanellas A; Verneuil HD
    Ann Biol Clin (Paris); 1999; 57(1):43-50. PubMed ID: 9920966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
    Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of the major splice donor and redefinition of cis-acting sequences of gutless feline foamy virus vectors.
    Liu W; Backes P; Löchelt M
    Virology; 2009 Nov; 394(2):208-17. PubMed ID: 19775717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector.
    Bai Y; Soda Y; Izawa K; Tanabe T; Kang X; Tojo A; Hoshino H; Miyoshi H; Asano S; Tani K
    Gene Ther; 2003 Aug; 10(17):1446-57. PubMed ID: 12900759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical gene therapy using recombinant adeno-associated virus vectors.
    Mueller C; Flotte TR
    Gene Ther; 2008 Jun; 15(11):858-63. PubMed ID: 18418415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-cycle dependence of foamy virus vectors.
    Patton GS; Erlwein O; McClure MO
    J Gen Virol; 2004 Oct; 85(Pt 10):2925-2930. PubMed ID: 15448354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foamy virus vectors for suicide gene therapy.
    Nestler U; Heinkelein M; Lücke M; Meixensberger J; Scheurlen W; Kretschmer A; Rethwilm A
    Gene Ther; 1997 Nov; 4(11):1270-7. PubMed ID: 9425452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foamy virus--adenovirus hybrid vectors.
    Picard-Maureau M; Kreppel F; Lindemann D; Juretzek T; Herchenröder O; Rethwilm A; Kochanek S; Heinkelein M
    Gene Ther; 2004 Apr; 11(8):722-8. PubMed ID: 14724670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y; Li Z; Li L; Li J; Liu X; Li W
    Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.
    Bauer TR; Tuschong LM; Calvo KR; Shive HR; Burkholder TH; Karlsson EK; West RR; Russell DW; Hickstein DD
    Mol Ther; 2013 May; 21(5):964-72. PubMed ID: 23531552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors.
    Heinkelein M; Hoffmann U; Lücke M; Imrich H; Müller JG; Meixensberger J; Westphahl M; Kretschmer A; Rethwilm A
    Cancer Gene Ther; 2005 Dec; 12(12):947-53. PubMed ID: 15905857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foamy virus vectors.
    Mergia A; Heinkelein M
    Curr Top Microbiol Immunol; 2003; 277():131-59. PubMed ID: 12908771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies on cellular gene regulation by HIV-1 based vectors: implications for quality control of vector production.
    Zhao Y; Azam S; Thorpe R
    Gene Ther; 2005 Feb; 12(4):311-9. PubMed ID: 15550925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.
    Bauer TR; Allen JM; Hai M; Tuschong LM; Khan IF; Olson EM; Adler RL; Burkholder TH; Gu YC; Russell DW; Hickstein DD
    Nat Med; 2008 Jan; 14(1):93-7. PubMed ID: 18157138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.